Danai Ktena: Assessing the Impact of Anti-PD-1/PD-L1 Inhibitors on Cancer Care in Greece
Danai Ktena, Health Policy Manager at MSD Greece, shared a post on LinkedIn:
“Just released in the Journal of Cancer Policy, our article that presents the differences between a world in which cancer patients across 7 indications are treated with anti-PD (L)1 inhibitors, versus a world where they receive previous standard-of-care (SoC).
Over a 5-year horizon, results of the HIP model indicated that anti-PD-(L)1s’ introduction in Greece is associated with significant health benefits that can be achieved at a manageable economic impact, making investment in immunooncology and sustainable patient access key aspects in elevating cancer care.
On a personal note, as this article is a collaborative result, I would like to thank Alexander Roediger, Evie Dalakaki, Sherneca Clarke-Melville, Ioannis Dimitriadis, Kostas Athanasakis, Panagiota Naoum, Robert Hughes, and Grace Mountain, for their support and contribution!”
Title: Assessing the impact of anti-PD-1/PD-L1 inhibitors on cancer care, health, and budget in Greece
Journal: Journal of Cancer Policy
Authors: Danai Ktena, Panagiota Naoum, Evie Dalakaki, Yiannis Dimitriadis, Grace Mountain, Robert Hughes, Sherneca Clarke-Melville, Alexander Roediger, Kostas Athanasakis
Alexander Roediger, Associate Vice-President, Global Lead Oncology Policy at Merck (MSD), shared this post, adding:
“Finding the spot where patient access, innovation and sustainable budget meet – that’s the story behind this nice publication.
Well done.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023